Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | MicrobiomeTrials← Back to trialsNCT04222413
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2020-10-27Est. Completion: 2027-12-31
Enrollment target: 116 participants Locations- University of Kansas, Fairway, Kansas, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Solid CancerHaematological Malignancies
This is an open-label, single-centre, category 2 "Jardé Law" proof-of-concept study designed to demonstrate the feasibil…
Toulouse, FranceEst. completion May 19, 2027
Advanced/Metastatic Non-Small Cell Lung Cancer
This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metas…
Goodyear, United StatesEst. completion Jun 24, 2030
This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed…
Huntersville, United StatesCompleted Apr 1, 2025